2,204
Views
17
CrossRef citations to date
0
Altmetric
Original Articles

Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation

, , , , , , , , & show all
Pages 840-852 | Received 19 Mar 2019, Accepted 17 Jul 2019, Published online: 27 Aug 2019

References

  • Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255.
  • Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
  • European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599–641.
  • Hyun MH, Lee YS, Kim JH, et al. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies. Hepatology. 2018;68:977–993.
  • Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.
  • Wáng YX, De Baere T, Idée JM, et al. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res. 2015;27:96–121.
  • Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol. 2012;39:503–509.
  • Farinati F, Giacomin A, Vanin V, et al. TACE treatment in hepatocellular carcinoma: what should we do now? J Hepatol. 2012;57:221–222.
  • Nakazawa T, Kokubu S, Shibuya A, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. Am J Roentgenol. 2007;188:480–488.
  • Shady W, Petre EN, Gonen M, et al. Percutaneous radiofrequency ablation of colorectal cancerliver metastases: factors affecting outcomes–a 10-year experience at a single center. Radiology. 2016;278:601–611.
  • Wang X, Sofocleous CT, Erinjeri JP, et al. Margin size is an independent predictor of local tumor progression after ablation of coloncancer liver metastases. Cardiovasc Intervent Radiol. 2013;36:166–175.
  • Andreano A, Huang Y, Meloni MF, et al. Microwaves create larger ablations than radiofrequency when controlled for power in ex vivo tissue. Med Phys. 2010;37:2967–2973.
  • Brace CL, Hinshaw JL, Laeseke PF, et al. Pulmonary thermal ablation: comparison of radiofrequency and microwave devices by using gross pathologic and CT findings in a swine model. Radiology. 2009;251:705–711.
  • Gillams AR, Lees WR. Radiofrequency ablation of lung metastases: factors influencing success. Eur Radiol. 2008;18:672–677.
  • Crocetti L, Bozzi E, Faviana P, et al. Thermal ablation of lung tissue: in vivo experimental comparison of microwave and radiofrequency. Cardiovasc Intervent Radiol. 2010;33:818–827.
  • Shady W, Petre EN, Gonen M, et al. Percutaneous microwave versus radiofrequency ablation of colon cancer liver metastases: ablation with clear margins (A0) provides the best local tumor control. J Vasc Interv Radiol. 2018;29:268–275.
  • Hoffmann R, Rempp H, Erhard L, et al. Comparison of four microwave ablation devices: an experimental study in ex vivo bovine liver. Radiology. 2013;268:89–97.
  • Lubner MG, Brace CL, Hinshaw JL, et al. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol. 2010;21:S192–S203.
  • Xu LF, Sun HL, Chen YT, et al. Large primary hepatocellular carcinoma: transarterialchemoembolization monotherapy versus combined transarterialchemoembolization-percutaneous microwave coagulationtherapy. J Gastroenterol Hepatol. 2013;28:456–463.
  • Chen QF, Jia ZY, Yang ZQ, et al. Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-microwave ablation therapy for hepatocellular carcinoma tumors ≤5 cm: a propensity analysis at a single center. Cardiovasc Intervent Radiol. 2017;40:1748–1755.
  • Veltri A, Gazzera C, Calandri M, et al. Percutaneous treatment of Hepatocellular carcinoma exceeding 3 cm: combined therapy or microwave ablation? Preliminary results. Radiol Med. 2015;120:1177–1183.
  • Maluccio M, Covey AM, Gandhi R, et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol. 2005;16:955–961.
  • Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–928.
  • Mohammadi H, Abuodeh Y, Jin W, et al. Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma. J Gastrointest Oncol. 2018;9:840–846.
  • Hiraoka A, Kumada T, Kudo M, et al. Albumin-Bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child-Pugh classifications. Liver Cancer. 2017;6:204–215.
  • Pinato DJ, Sharma R, Allara E, et al. The ALBI grade provides objective hepatic reserve estimationacross each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66:338–346.
  • Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550–558.
  • Hansmann J, Evers MJ, Bui JT, et al. Albumin-bilirubin and platelet-albumin-bilirubin grades accurately predict overall survival in high-risk patients undergoing conventional transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2017;28:1224–1231.
  • Jaruvongvanich V, Sempokuya T, Wong L. Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma? J Gastrointest Oncol. 2018;9:750–761.
  • Elshaarawy O, Alkhatib A, Elhelbawy M, et al. Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma. World J Hepatol. 2019;11:542–552.
  • Kao WY, Su CW, Chiou YY, et al. Hepatocellular carcinoma: nomograms based on the albumin-bilirubin grade to assess the outcomes of radiofrequency ablation. Radiology. 2017;285:670–680.
  • Filippiadis DK, Binkert C, Pellerin O, et al. Cirse quality assurance document and standards for classification of complications: the Cirse Classification System. Cardiovasc Intervent Radiol. 2017;40:1141–1146.
  • Liu PH, Hsu CY, Hsia CY, et al. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. J Gastroenterol Hepatol. 2017;32:879–886.
  • Katsanos K, Kitrou P, Spiliopoulos S, et al. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0184597.
  • Zheng L, Li HL, Guo CY, et al. Comparison of the efficacy and prognostic factors of transarterial chemoembolization plus microwave ablation versus transarterial chemoembolization alone in patients with a large solitary or multinodular hepatocellular carcinomas. Korean J Radiol. 2018;19:237–246.
  • Hu H, Chen GF, Yuan W, et al. Microwave ablation with chemoembolization for large hepatocellular carcinoma in patientswith cirrhosis. Int J Hyperthermia. 2018;34:1351–1358.
  • Elnekave E, Erinjeri JP, Brown KT, et al. Long-term outcomes comparing surgery to embolization-ablation for treatment of solitary HCC <7 cm. Ann Surg Oncol. 2013;20:2881–2886.
  • Ho CHM, Chiang CL, Lee FAS, et al. Comparison of platelet-albumin-bilirubin (PALBI), albumin-bilirubin (ALBI),and child-pugh (CP) score for predicting of survival in advanced HCC patients receiving radiotherapy (RT). Oncotarget. 2018;9:28818–28829.
  • Kim KW, Lee JM, Klotz E, et al. Safety margin assessment after radiofrequency ablation of the liver using registration of preprocedure and postprocedure CT images. Am J of Roentgenol. 2011;196:W565–W572.
  • Shin S, Lee JM, Kim KW, et al. Postablation assessment using follow-up registration of CT images before and after radiofrequency ablation (RFA): Prospective evaluation of midterm therapeutic results of RFA for hepatocellular carcinoma. Am J of Roentgenol. 2014;203:70–77.
  • Kaye EA, Cornelis FH, Petre EN, et al. Volumetric 3D assessment of ablation zones after thermal abltion of colorectal liver metastases to improve prediction of local tumor progression. Eur Radiol. 2019;29:2698–2705.
  • Solbiati M, Muglia R, Goldberg SN, et al. A novel software platform for volumetric assessment of ablation completeness. Int J Hyperthermia. 2019;36:337–343.